Literature DB >> 9442022

Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake.

H L Dichek1, W Brecht, J Fan, Z S Ji, S P McCormick, H Akeefe, L Conzo, D A Sanan, K H Weisgraber, S G Young, J M Taylor, R W Mahley.   

Abstract

To determine the mechanisms by which human hepatic lipase (HL) contributes to the metabolism of apolipoprotein (apo) B-containing lipoproteins and high density lipoproteins (HDL) in vivo, we developed and characterized HL transgenic mice. HL was localized by immunohistochemistry to the liver and to the adrenal cortex. In hemizygous (hHLTg+/0) and homozygous (hHLTg+/+) mice, postheparin plasma HL activity increased by 25- and 50-fold and plasma cholesterol levels decreased by 80% and 85%, respectively. In mice fed a high fat, high cholesterol diet to increase endogenous apoB-containing lipoproteins, plasma cholesterol decreased 33% (hHLTg+/0) and 75% (hHLTg+/+). Both apoB-containing remnant lipoproteins and HDL were reduced. To extend this observation, the HL transgene was expressed in human apoB transgenic (huBTg) and apoE-deficient (apoE-/-) mice, both of which have high plasma levels of apoB-containing lipoproteins. (Note that the huBTg mice that were used in these studies were all hemizygous for the human apoB gene.) In both the huBTg,hHLTg+/0 mice and the apoE-/-,hHLTg+/0 mice, plasma cholesterol decreased by 50%. This decrease was reflected in both the apoB-containing and the HDL fractions. To determine if HL catalytic activity is required for these decreases, we expressed catalytically inactive HL (HL-CAT) in apoE-/- mice. The postheparin plasma HL activities were similar in the apoE-/- and the apoE-/-,HL-CAT+/0 mice, reflecting the activity of the endogenous mouse HL and confirming that the HL-CAT was catalytically inactive. However, the postheparin plasma HL activity was 20-fold higher in the apoE-/-,hHLTg+/0 mice, indicating expression of the active human HL. Immunoblotting demonstrated high levels of human HL in postheparin plasma of both apoE-/-,hHLTg+/0 and apoE-/-,HL-CAT+/0 mice. Plasma cholesterol and apoB-containing lipoprotein levels were approximately 60% lower in apoE-/-,HL-CAT+/0 mice than in apoE-/- mice. However, the HDL were only minimally reduced. Thus, the catalytic activity of HL is critical for its effects on HDL but not for its effects on apoB-containing lipoproteins. These results provide evidence that HL can act as a ligand to remove apoB-containing lipoproteins from plasma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442022     DOI: 10.1074/jbc.273.4.1896

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  FoxO transcription factors are required for hepatic HDL cholesterol clearance.

Authors:  Samuel X Lee; Markus Heine; Christian Schlein; Rajasekhar Ramakrishnan; Jing Liu; Gabriella Belnavis; Ido Haimi; Alexander W Fischer; Henry N Ginsberg; Joerg Heeren; Franz Rinninger; Rebecca A Haeusler
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

2.  Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase.

Authors:  N Bergeron; L Kotite; M Verges; P Blanche; R L Hamilton; R M Krauss; A Bensadoun; R J Havel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Lipase maturation factor 1 is required for endothelial lipase activity.

Authors:  Osnat Ben-Zeev; Maryam Hosseini; Ching-Mei Lai; Nicole Ehrhardt; Howard Wong; Angelo B Cefalù; Davide Noto; Maurizio R Averna; Mark H Doolittle; Miklós Péterfy
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

4.  The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance.

Authors:  Melinde Wijers; Paolo Zanoni; Nalan Liv; Dyonne Y Vos; Michelle Y Jäckstein; Marieke Smit; Sanne Wilbrink; Justina C Wolters; Ydwine T van der Veen; Nicolette Huijkman; Daphne Dekker; Niels Kloosterhuis; Theo H van Dijk; Daniel D Billadeau; Folkert Kuipers; Judith Klumperman; Arnold von Eckardstein; Jan Albert Kuivenhoven; Bart van de Sluis
Journal:  JCI Insight       Date:  2019-06-06

5.  Removal of chylomicron remnants in transgenic mice overexpressing normal and membrane-anchored hepatic lipase.

Authors:  Sung-Joon Lee; Sujata Kadambi; Kenneth C-W Yu; Christopher David; Salman Azhar; Allen D Cooper; Sungshin Y Choi
Journal:  J Lipid Res       Date:  2004-11-01       Impact factor: 5.922

6.  Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins.

Authors:  Robert J Brown; William R Lagor; Sandhya Sankaranaravanan; Tomoyuki Yasuda; Thomas Quertermous; George H Rothblat; Daniel J Rader
Journal:  Circ Res       Date:  2010-06-17       Impact factor: 17.367

7.  Lipidomic analyses of female mice lacking hepatic lipase and endothelial lipase indicate selective modulation of plasma lipid species.

Authors:  Yanbo Yang; Takashi Kuwano; William R Lagor; Carolyn J Albert; Siobhan Brenton; Daniel J Rader; David A Ford; Robert J Brown
Journal:  Lipids       Date:  2014-04-29       Impact factor: 1.880

8.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

9.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

10.  Hormonal regulation of testicular steroid and cholesterol homeostasis.

Authors:  Stephen M Eacker; Nalini Agrawal; Kun Qian; Helén L Dichek; Eun-Yeung Gong; Keesook Lee; Robert E Braun
Journal:  Mol Endocrinol       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.